Information on the target
EVERITA Capital, a private equity fund specializing in growth investments within small and medium-sized enterprises across Central Europe, has successfully acquired a majority stake in CLINTRIAL s.r.o., a well-established provider of clinical trial services based in Prague. Founded by Dr. Zdeněk Šolle and his wife Barbora, CLINTRIAL has built a strong reputation over more than two decades in the clinical research sector. The financial specifics of the transaction remain undisclosed, but the company has participated in over 100 Phase II and III clinical trials for global pharmaceutical firms, enrolling more than 1,000 patients.
With a dedicated team of over 30 professionals and a network of specialist physicians throughout the Czech Republic, CLINTRIAL focuses on core therapeutic areas such as psychiatry, dermatology, neurology, and rheumatology. In 2025, the company reported revenues exceeding CZK 60 million, reflecting its significant role in the clinical research landscape.
Industry overview in the target’s specific country
The Pharmaceuticals (NEC) industry in the Czech Republic is characterized by a robust framework for clinical research, which has been bolstered by the country's long-standing tradition in this field. The Czech Republic boasts a higher-than-average number of clinical trials per capita compared to the European Union, with over 500 clinical trials currently active and involving approximately 17,400 patients. This environment not only supports the growth of companies like CLINTRIAL but also attracts substantial investment from pharmaceutical companies.
Investment in clinical trials in the Czech Republic is significant, with an estimated annual expenditure of CZK 3 billion by pharmaceutical firms. This investment not only enhances the research capabilities within the country but also generates additional savings exceeding CZK 2 billion for the healthcare system. The strategic importance of clinical research is further underscored by recent policy initiatives, including the introduction of the National Clinical Trials Strategy by the Czech Ministry of Health.
At the European level, clinical research has been prioritized within the life sciences strategy, reflecting a growing recognition of its importance in advancing healthcare solutions. This supportive policy environment, combined with the country's skilled workforce and established infrastructure, positions the Czech Republic as a favorable location for clinical research and development activities.
The rationale behind the deal The acquisition of CLINTRIAL by EVERITA Capital aligns with the growing demand for high-quality clinical research services in an increasingly complex pharmaceutical landscape. By leveraging CLINTRIAL's established platform, EVERITA aims to enhance the company's operationa…